SuicidDentistV1, Main, Exploration, bibRecord, 000030

Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.

Identifieur interne : 000030 ( Main/Exploration ); précédent : 000029; suivant : 000031

Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.

Auteurs : Ana Laura Soares [Brésil] ; Sérgio Simon [Brésil] ; Luiz Henrique Gebrim [Brésil] ; Afonso Celso P. Nazário [Brésil] ; Marise Lazaretti-Castro [Brésil]

Source :

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [ 1433-7339 ] ; 2020.

RBID : pubmed:31468192

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Agents de maintien de la densité osseuse (effets indésirables), Agents de maintien de la densité osseuse (usage thérapeutique), Diphosphonates (effets indésirables), Diphosphonates (usage thérapeutique), Facteurs de risque (MeSH), Femelle (MeSH), Hormone parathyroïdienne (sang), Humains (MeSH), Marqueurs biologiques (sang), Ostéocalcine (sang), Ostéonécrose de la mâchoire associée aux biphosphonates (sang), Ostéonécrose de la mâchoire associée aux biphosphonates (épidémiologie), Ostéoporose (sang), Ostéoporose (traitement médicamenteux), Prévalence (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Tumeurs du sein (sang), Tumeurs du sein (traitement médicamenteux), Vitamine D (analogues et dérivés), Vitamine D (sang), Études transversales (MeSH).
MESH :
- analogues et dérivés : Vitamine D.
- effets indésirables : Agents de maintien de la densité osseuse, Diphosphonates.
- sang : Hormone parathyroïdienne, Marqueurs biologiques, Ostéocalcine, Ostéonécrose de la mâchoire associée aux biphosphonates, Ostéoporose, Tumeurs du sein, Vitamine D.
- traitement médicamenteux : Ostéoporose, Tumeurs du sein.
- usage thérapeutique : Agents de maintien de la densité osseuse, Diphosphonates.
- épidémiologie : Ostéonécrose de la mâchoire associée aux biphosphonates.
- Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Humains, Prévalence, Sujet âgé, Sujet âgé de 80 ans ou plus, Études transversales.

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Biomarkers (blood), Bisphosphonate-Associated Osteonecrosis of the Jaw (blood), Bisphosphonate-Associated Osteonecrosis of the Jaw (epidemiology), Bone Density Conservation Agents (adverse effects), Bone Density Conservation Agents (therapeutic use), Breast Neoplasms (blood), Breast Neoplasms (drug therapy), Cross-Sectional Studies (MeSH), Diphosphonates (adverse effects), Diphosphonates (therapeutic use), Female (MeSH), Humans (MeSH), Middle Aged (MeSH), Osteocalcin (blood), Osteoporosis (blood), Osteoporosis (drug therapy), Parathyroid Hormone (blood), Prevalence (MeSH), Risk Factors (MeSH), Vitamin D (analogs & derivatives), Vitamin D (blood).
MESH :
- chemical , adverse effects : Bone Density Conservation Agents, Diphosphonates.
- chemical , analogs & derivatives : Vitamin D.
- chemical , blood : Biomarkers, Osteocalcin, Parathyroid Hormone, Vitamin D.
- blood : Bisphosphonate-Associated Osteonecrosis of the Jaw, Breast Neoplasms, Osteoporosis.
- drug therapy : Breast Neoplasms, Osteoporosis.
- epidemiology : Bisphosphonate-Associated Osteonecrosis of the Jaw.
- chemical , therapeutic use : Bone Density Conservation Agents, Diphosphonates.
- Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Middle Aged, Prevalence, Risk Factors.

Abstract

PURPOSE

Medication-related osteonecrosis of the jaw (MRONJ) has been reported as a side effect of bisphosphonate (BP). The aim of this study was to identify the prevalence of MRONJ in women taking BP for osteoporosis and for metastatic breast cancer and correlate it with risk factors and biochemical markers of bone metabolism.

METHODS

Patients taking oral or intravenous BP with osteoporosis (G1; n = 153; median 72.8 years) and with metastatic breast cancer (G2; n = 134; median 58.2 years) had their hospital charts reviewed, were submitted to dental inspection, and answered a health questionnaire. Fasting blood samples were randomly collected from both groups to measure osteocalcin, carboxy-terminal cross-linking telopeptide of type I collagen, intact parathyroid hormone and procollagen type 1 amino-terminal propeptide (P1NP), 25 hydroxyvitamin D (25OHD), creatinine, and total calcium.

RESULTS

G1 was older (p = 0.001) and had more cases of diabetes (p = 0.043). P1NP was higher (p = 0.022) and 25OHD lower (p = 0.004) in G2 compared with G1. MRONJ was not found in the G1, whereas 4 cases (3%) were detected in G2. Positive risk factors for MRONJ were number of BP doses and number of visits to the dentist and dental extractions. The biochemical parameters, however, could not identify those who developed MRONJ.

CONCLUSIONS

The prevalence of MRONJ was 3% in women with metastatic breast cancer receiving BP. No cases were identified in women receiving oral BP chronically for osteoporosis. P1NP was higher in women with metastatic breast cancer, even during treatment with antiresorptives, but could not differentiate those with MRONJ.

DOI: 10.1007/s00520-019-05044-0
PubMed: 31468192

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000056
to stream Main, to step Curation: 000056

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.</title>
<author><name sortKey="Soares, Ana Laura" sort="Soares, Ana Laura" uniqKey="Soares A" first="Ana Laura" last="Soares">Ana Laura Soares</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Endocrinology, Escola Paulista de Medicina - UNIFESP and Oral Medicine Department, Hospital Oswaldo Cruz, São Paulo, Brazil. anasoaresbr@yahoo.com.br.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Division of Endocrinology, Escola Paulista de Medicina - UNIFESP and Oral Medicine Department, Hospital Oswaldo Cruz, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Simon, Sergio" sort="Simon, Sergio" uniqKey="Simon S" first="Sérgio" last="Simon">Sérgio Simon</name>
<affiliation wicri:level="3"><nlm:affiliation>Centro Paulista de Oncologia, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Centro Paulista de Oncologia, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gebrim, Luiz Henrique" sort="Gebrim, Luiz Henrique" uniqKey="Gebrim L" first="Luiz Henrique" last="Gebrim">Luiz Henrique Gebrim</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Pérola Byington, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Hospital Pérola Byington, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nazario, Afonso Celso P" sort="Nazario, Afonso Celso P" uniqKey="Nazario A" first="Afonso Celso P" last="Nazário">Afonso Celso P. Nazário</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Gynecology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Department of Gynecology, Escola Paulista de Medicina, UNIFESP, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lazaretti Castro, Marise" sort="Lazaretti Castro, Marise" uniqKey="Lazaretti Castro M" first="Marise" last="Lazaretti-Castro">Marise Lazaretti-Castro</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Endocrinology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Division of Endocrinology, Escola Paulista de Medicina, UNIFESP, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31468192</idno>
<idno type="pmid">31468192</idno>
<idno type="doi">10.1007/s00520-019-05044-0</idno>
<idno type="wicri:Area/Main/Corpus">000056</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000056</idno>
<idno type="wicri:Area/Main/Curation">000056</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000056</idno>
<idno type="wicri:Area/Main/Exploration">000056</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.</title>
<author><name sortKey="Soares, Ana Laura" sort="Soares, Ana Laura" uniqKey="Soares A" first="Ana Laura" last="Soares">Ana Laura Soares</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Endocrinology, Escola Paulista de Medicina - UNIFESP and Oral Medicine Department, Hospital Oswaldo Cruz, São Paulo, Brazil. anasoaresbr@yahoo.com.br.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Division of Endocrinology, Escola Paulista de Medicina - UNIFESP and Oral Medicine Department, Hospital Oswaldo Cruz, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Simon, Sergio" sort="Simon, Sergio" uniqKey="Simon S" first="Sérgio" last="Simon">Sérgio Simon</name>
<affiliation wicri:level="3"><nlm:affiliation>Centro Paulista de Oncologia, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Centro Paulista de Oncologia, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gebrim, Luiz Henrique" sort="Gebrim, Luiz Henrique" uniqKey="Gebrim L" first="Luiz Henrique" last="Gebrim">Luiz Henrique Gebrim</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Pérola Byington, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Hospital Pérola Byington, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nazario, Afonso Celso P" sort="Nazario, Afonso Celso P" uniqKey="Nazario A" first="Afonso Celso P" last="Nazário">Afonso Celso P. Nazário</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Gynecology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Department of Gynecology, Escola Paulista de Medicina, UNIFESP, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lazaretti Castro, Marise" sort="Lazaretti Castro, Marise" uniqKey="Lazaretti Castro M" first="Marise" last="Lazaretti-Castro">Marise Lazaretti-Castro</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Endocrinology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Division of Endocrinology, Escola Paulista de Medicina, UNIFESP, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</title>
<idno type="eISSN">1433-7339</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Biomarkers (blood)</term>
<term>Bisphosphonate-Associated Osteonecrosis of the Jaw (blood)</term>
<term>Bisphosphonate-Associated Osteonecrosis of the Jaw (epidemiology)</term>
<term>Bone Density Conservation Agents (adverse effects)</term>
<term>Bone Density Conservation Agents (therapeutic use)</term>
<term>Breast Neoplasms (blood)</term>
<term>Breast Neoplasms (drug therapy)</term>
<term>Cross-Sectional Studies (MeSH)</term>
<term>Diphosphonates (adverse effects)</term>
<term>Diphosphonates (therapeutic use)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Osteocalcin (blood)</term>
<term>Osteoporosis (blood)</term>
<term>Osteoporosis (drug therapy)</term>
<term>Parathyroid Hormone (blood)</term>
<term>Prevalence (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>Vitamin D (analogs & derivatives)</term>
<term>Vitamin D (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Agents de maintien de la densité osseuse (effets indésirables)</term>
<term>Agents de maintien de la densité osseuse (usage thérapeutique)</term>
<term>Diphosphonates (effets indésirables)</term>
<term>Diphosphonates (usage thérapeutique)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Hormone parathyroïdienne (sang)</term>
<term>Humains (MeSH)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Ostéocalcine (sang)</term>
<term>Ostéonécrose de la mâchoire associée aux biphosphonates (sang)</term>
<term>Ostéonécrose de la mâchoire associée aux biphosphonates (épidémiologie)</term>
<term>Ostéoporose (sang)</term>
<term>Ostéoporose (traitement médicamenteux)</term>
<term>Prévalence (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Tumeurs du sein (sang)</term>
<term>Tumeurs du sein (traitement médicamenteux)</term>
<term>Vitamine D (analogues et dérivés)</term>
<term>Vitamine D (sang)</term>
<term>Études transversales (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bone Density Conservation Agents</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Vitamin D</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term>
<term>Osteocalcin</term>
<term>Parathyroid Hormone</term>
<term>Vitamin D</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Vitamine D</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Bisphosphonate-Associated Osteonecrosis of the Jaw</term>
<term>Breast Neoplasms</term>
<term>Osteoporosis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term>
<term>Osteoporosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Bisphosphonate-Associated Osteonecrosis of the Jaw</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hormone parathyroïdienne</term>
<term>Marqueurs biologiques</term>
<term>Ostéocalcine</term>
<term>Ostéonécrose de la mâchoire associée aux biphosphonates</term>
<term>Ostéoporose</term>
<term>Tumeurs du sein</term>
<term>Vitamine D</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Density Conservation Agents</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Ostéoporose</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term>
<term>Diphosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ostéonécrose de la mâchoire associée aux biphosphonates</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cross-Sectional Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Prevalence</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Prévalence</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études transversales</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b>
</p>
<p>Medication-related osteonecrosis of the jaw (MRONJ) has been reported as a side effect of bisphosphonate (BP). The aim of this study was to identify the prevalence of MRONJ in women taking BP for osteoporosis and for metastatic breast cancer and correlate it with risk factors and biochemical markers of bone metabolism.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Patients taking oral or intravenous BP with osteoporosis (G1; n = 153; median 72.8 years) and with metastatic breast cancer (G2; n = 134; median 58.2 years) had their hospital charts reviewed, were submitted to dental inspection, and answered a health questionnaire. Fasting blood samples were randomly collected from both groups to measure osteocalcin, carboxy-terminal cross-linking telopeptide of type I collagen, intact parathyroid hormone and procollagen type 1 amino-terminal propeptide (P1NP), 25 hydroxyvitamin D (25OHD), creatinine, and total calcium.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>G1 was older (p = 0.001) and had more cases of diabetes (p = 0.043). P1NP was higher (p = 0.022) and 25OHD lower (p = 0.004) in G2 compared with G1. MRONJ was not found in the G1, whereas 4 cases (3%) were detected in G2. Positive risk factors for MRONJ were number of BP doses and number of visits to the dentist and dental extractions. The biochemical parameters, however, could not identify those who developed MRONJ.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>The prevalence of MRONJ was 3% in women with metastatic breast cancer receiving BP. No cases were identified in women receiving oral BP chronically for osteoporosis. P1NP was higher in women with metastatic breast cancer, even during treatment with antiresorptives, but could not differentiate those with MRONJ.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31468192</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-7339</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>28</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>
<ISOAbbreviation>Support Care Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.</ArticleTitle>
<Pagination><MedlinePgn>2265-2271</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-019-05044-0</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Medication-related osteonecrosis of the jaw (MRONJ) has been reported as a side effect of bisphosphonate (BP). The aim of this study was to identify the prevalence of MRONJ in women taking BP for osteoporosis and for metastatic breast cancer and correlate it with risk factors and biochemical markers of bone metabolism.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients taking oral or intravenous BP with osteoporosis (G1; n = 153; median 72.8 years) and with metastatic breast cancer (G2; n = 134; median 58.2 years) had their hospital charts reviewed, were submitted to dental inspection, and answered a health questionnaire. Fasting blood samples were randomly collected from both groups to measure osteocalcin, carboxy-terminal cross-linking telopeptide of type I collagen, intact parathyroid hormone and procollagen type 1 amino-terminal propeptide (P1NP), 25 hydroxyvitamin D (25OHD), creatinine, and total calcium.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">G1 was older (p = 0.001) and had more cases of diabetes (p = 0.043). P1NP was higher (p = 0.022) and 25OHD lower (p = 0.004) in G2 compared with G1. MRONJ was not found in the G1, whereas 4 cases (3%) were detected in G2. Positive risk factors for MRONJ were number of BP doses and number of visits to the dentist and dental extractions. The biochemical parameters, however, could not identify those who developed MRONJ.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prevalence of MRONJ was 3% in women with metastatic breast cancer receiving BP. No cases were identified in women receiving oral BP chronically for osteoporosis. P1NP was higher in women with metastatic breast cancer, even during treatment with antiresorptives, but could not differentiate those with MRONJ.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soares</LastName>
<ForeName>Ana Laura</ForeName>
<Initials>AL</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-3927-0289</Identifier>
<AffiliationInfo><Affiliation>Division of Endocrinology, Escola Paulista de Medicina - UNIFESP and Oral Medicine Department, Hospital Oswaldo Cruz, São Paulo, Brazil. anasoaresbr@yahoo.com.br.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Simon</LastName>
<ForeName>Sérgio</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Centro Paulista de Oncologia, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gebrim</LastName>
<ForeName>Luiz Henrique</ForeName>
<Initials>LH</Initials>
<AffiliationInfo><Affiliation>Hospital Pérola Byington, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nazário</LastName>
<ForeName>Afonso Celso P</ForeName>
<Initials>ACP</Initials>
<AffiliationInfo><Affiliation>Department of Gynecology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lazaretti-Castro</LastName>
<ForeName>Marise</ForeName>
<Initials>M</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-9186-2834</Identifier>
<AffiliationInfo><Affiliation>Division of Endocrinology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>2007/03845-0</GrantID>
<Agency>FAPESP</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Support Care Cancer</MedlineTA>
<NlmUniqueID>9302957</NlmUniqueID>
<ISSNLinking>0941-4355</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>104982-03-8</RegistryNumber>
<NameOfSubstance UI="D015675">Osteocalcin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>1406-16-2</RegistryNumber>
<NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>A288AR3C9H</RegistryNumber>
<NameOfSubstance UI="C104450">25-hydroxyvitamin D</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059266" MajorTopicYN="N">Bisphosphonate-Associated Osteonecrosis of the Jaw</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015675" MajorTopicYN="N">Osteocalcin</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bisphosphonates</Keyword>
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">Medication-related osteonecrosis</Keyword>
<Keyword MajorTopicYN="N">Osteoporosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>11</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>08</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>8</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>8</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31468192</ArticleId>
<ArticleId IdType="doi">10.1007/s00520-019-05044-0</ArticleId>
<ArticleId IdType="pii">10.1007/s00520-019-05044-0</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Support Care Cancer. 2015 Dec;23(12):3421-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25757408</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25234529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 2007 Jul-Aug;27(4A):1961-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17649805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12966493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Bone Miner Res. 2015 Jan;30(1):3-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25414052</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Oral Maxillofac Surg. 2017 Feb;46(2):151-156</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27876532</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep;106(3):389-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18554944</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2012 May;23(5):1341-1347</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21986094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Odontology. 2016 Sep;104(3):363-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25956267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24(1):e26-e36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30595601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):ix</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26362366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Assoc Oral Maxillofac Surg. 2016 Dec;42(6):365-369</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28053907</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Bone Miner Res. 2009 Apr;24(4):561-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19257812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18022461</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoporos Int. 2014 Mar;25(3):1131-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24343364</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Jun;127(6):504-515</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30962171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Oct;124(4):367-368</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30084362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):479-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26293329</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Oral Maxillofac Surg. 2016 Apr;74(4):738-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26501428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Osteoporos Rep. 2010 Mar;8(1):40-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20425090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Oral Maxillofac Surg. 2007 Mar;65(3):369-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17307580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Craniofac Surg. 2018 Mar;29(2):e137-e140</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29215447</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Craniomaxillofac Surg. 2017 Dec;45(12):2068-2074</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29102331</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2014 Aug 1;20(15):3955-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24958808</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocr Rev. 1998 Feb;19(1):80-100</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9494781</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2006 Jun;7(6):508-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16750501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Brésil</li>
</country>
<region><li>État de São Paulo</li>
</region>
<settlement><li>São Paulo</li>
</settlement>
</list>
<tree><country name="Brésil"><region name="État de São Paulo"><name sortKey="Soares, Ana Laura" sort="Soares, Ana Laura" uniqKey="Soares A" first="Ana Laura" last="Soares">Ana Laura Soares</name>
</region>
<name sortKey="Gebrim, Luiz Henrique" sort="Gebrim, Luiz Henrique" uniqKey="Gebrim L" first="Luiz Henrique" last="Gebrim">Luiz Henrique Gebrim</name>
<name sortKey="Lazaretti Castro, Marise" sort="Lazaretti Castro, Marise" uniqKey="Lazaretti Castro M" first="Marise" last="Lazaretti-Castro">Marise Lazaretti-Castro</name>
<name sortKey="Nazario, Afonso Celso P" sort="Nazario, Afonso Celso P" uniqKey="Nazario A" first="Afonso Celso P" last="Nazário">Afonso Celso P. Nazário</name>
<name sortKey="Simon, Sergio" sort="Simon, Sergio" uniqKey="Simon S" first="Sérgio" last="Simon">Sérgio Simon</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000030 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000030 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SuicidDentistV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31468192
   |texte=   Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31468192" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SuicidDentistV1

This area was generated with Dilib version V0.6.39.
Data generation: Sun Oct 3 17:04:29 2021. Site generation: Sun Oct 3 17:05:17 2021

	Serveur d'exploration sur le suicide chez les dentistes
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le suicide chez les dentistes

Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.

Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki